- FoI Number
- 2022-627
- Subject
- Medications
- Date Received
- 11/01/2023
- Request and Response
-
- How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs?
- Aubagio (teriflunomide) 0
- Avonex (interferon beta-1a) 0
- Betaferon (interferon beta-1b) 0
- Brabio (glatiramer acetate) 3
- Copaxone (glatiramer acetate) 0
- Extavia (beta interferon-1b) 1
- Gilenya (fingolimod) 1
- Lemtrada (alemtuzumab) 0
- Kesimpta (ofatumumab) 0
- Mavenclad (cladribine) 0
- Mayzent (siponimod) 0
- Ocrevus (ocrelizumab) 0
- Plegridy (peginterferon beta-1a) 0
- Ponvory (ponesimod) 0
- Rebif (beta interferon-1a) 0
- Tecfidera (dimethyl fumarate) 15
- Tysabri (natalizumab) 0
- Tysabri (natalizumab) pre-filled syringes ONLY 0
- Vumerity (diroximel fumarate) 0
- Zeposia (ozanimod) 0
- It would also be very helpful if you could advise how many hospital patients (inpatients or outpatients) currently have a diagnosis for the following conditions:
- Multiple sclerosis (any type)
- Relapsing remitting multiple sclerosis (RRMS)
- Primary progressive multiple sclerosis (PPMS)
- Secondary progressive multiple sclerosis (SPMS)
In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested.
NHS Shetland do not attach diagnosis codes to patients until they are discharged.
